Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy | Zendy

Henry N. Ginsberg | Zendy; Neil Hounslow | Zendy; Yusuke Senko | Zendy; Hideki Suganami | Zendy; Paweł Bogdański | Zendy; R Češka | Zendy; Ákos Kalina | Zendy; Р. А. Либис | Zendy; T. V. Supryadkina | Zendy; G. Kees Hovingh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy

Author(s) -

Henry N. Ginsberg,

Neil Hounslow,

Yusuke Senko,

Hideki Suganami,

Paweł Bogdański,

R Češka,

Ákos Kalina,

Р. А. Либис,

T. V. Supryadkina,

G. Kees Hovingh

Publication year - 2022

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc21-1288

Subject(s) - medicine , tolerability , hypertriglyceridemia , placebo , endocrinology , triglyceride , statin , fenofibrate , cholesterol , gastroenterology , adverse effect , alternative medicine , pathology

High plasma triglyceride (TG) is an independent risk factor for cardiovascular disease. Fibrates lower TG levels through peroxisome proliferator-activated receptor α (PPARα) agonism. Currently available fibrates, however, have relatively low selectivity for PPARα. The aim of this trial was to assess the safety, tolerability, and efficacy of K-877 (pemafibrate), a selective PPARα modulator, in statin-treated European patients with hypertriglyceridemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research